Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + lamivudine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Entecavir + lamivudine is a combination of two oral antiviral small molecules used in the management of chronic hepatitis B virus (HBV) infection, particularly in patients with prior resistance to lamivudine. Both drugs are nucleoside analogue reverse transcriptase inhibitors that target the HBV polymerase, inhibiting viral DNA synthesis and replication. Entecavir is a guanosine analogue with potent activity against HBV, while lamivudine is a cytidine analogue also active against HBV but prone to resistance development when used as monotherapy. The combination may be considered in certain clinical scenarios such as managing drug-resistant HBV or during transition between therapies[1][2][3].
- Brand names
- BaracludeEpivir-HBVZeffixHeptovir
- Other names
- ETV + LAMEntecavir and Lamivudine
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on entecavir + lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + lamivudine.